GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HitGen Inc (SHSE:688222) » Definitions » EV-to-EBIT

HitGen (SHSE:688222) EV-to-EBIT : 55.52 (As of May. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is HitGen EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, HitGen's Enterprise Value is ¥4,144.0 Mil. HitGen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥74.6 Mil. Therefore, HitGen's EV-to-EBIT for today is 55.52.

The historical rank and industry rank for HitGen's EV-to-EBIT or its related term are showing as below:

SHSE:688222' s EV-to-EBIT Range Over the Past 10 Years
Min: 54.07   Med: 165.02   Max: 468.45
Current: 55.84

During the past 8 years, the highest EV-to-EBIT of HitGen was 468.45. The lowest was 54.07. And the median was 165.02.

SHSE:688222's EV-to-EBIT is ranked worse than
87.74% of 424 companies
in the Biotechnology industry
Industry Median: 10 vs SHSE:688222: 55.84

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. HitGen's Enterprise Value for the quarter that ended in Mar. 2024 was ¥4,593.6 Mil. HitGen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥74.6 Mil. HitGen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.62%.


HitGen EV-to-EBIT Historical Data

The historical data trend for HitGen's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HitGen EV-to-EBIT Chart

HitGen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - 182.74 139.19 214.03 109.46

HitGen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 380.80 185.54 163.46 109.46 61.54

Competitive Comparison of HitGen's EV-to-EBIT

For the Biotechnology subindustry, HitGen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HitGen's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HitGen's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HitGen's EV-to-EBIT falls into.



HitGen EV-to-EBIT Calculation

HitGen's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4144.027/74.639
=55.52

HitGen's current Enterprise Value is ¥4,144.0 Mil.
HitGen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥74.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HitGen  (SHSE:688222) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

HitGen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=74.639/4593.5844
=1.62 %

HitGen's Enterprise Value for the quarter that ended in Mar. 2024 was ¥4,593.6 Mil.
HitGen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥74.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HitGen EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of HitGen's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


HitGen (SHSE:688222) Business Description

Traded in Other Exchanges
N/A
Address
No. 18, Section 2, Biocity Middle Road, Chengdu Tianfu International Biological City, Shuangliu District, Sichuan Province, Chengdu, CHN, 610093
HitGen Inc is engaged in drug research and development and provision of technical consultation, technology transfer, and technical services. The company uses DEL technology to provide research and development services for early drug discovery and transfer of new drug R&D projects.

HitGen (SHSE:688222) Headlines

No Headlines